Comparative Pharmacology
Head-to-head clinical analysis: CAPLYTA versus DAPIPRAZOLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPLYTA versus DAPIPRAZOLE HYDROCHLORIDE.
CAPLYTA vs DAPIPRAZOLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPLYTA (lumateperone) is a second-generation antipsychotic with a unique mechanism of action. It acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. It also functions as a serotonin transporter (SERT) inhibitor and has partial agonist activity at dopamine D1 receptors. Additionally, it modulates glutamate via effects on NMDA receptors and mTOR signaling.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
42 mg orally once daily, with or without food. Initiate at 42 mg/day; no dose titration required.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
None Documented
None Documented
The terminal elimination half-life of lumateperone is approximately 18 hours, supporting once-daily dosing with steady state achieved within 5 days.
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Following oral administration of lumateperone, approximately 81% of the dose is excreted in feces (mostly as metabolites) and 12% in urine (as metabolites). Less than 1% is excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic